https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-04-05 / Surg. Oncol. Clin. N. Am. 2019 Jul;28(3):447-464
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-04-05 / Surg. Oncol. Clin. N. Am. 2019 Jul;28(3):447-4642019-04-05 00:00:002019-04-05 00:00:00Immunotherapy in Ovarian Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-04-04 / BMC Cancer 2019 Apr;19(1):315
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-04-04 / BMC Cancer 2019 Apr;19(1):3152019-04-04 00:00:002020-12-14 17:17:19Regression of solid breast tumours in mice by Newcastle disease virus is associated with production of apoptosis related-cytokines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-04-01 / Urol Ann 2019 Apr-Jun;11(2):119-125
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-04-01 / Urol Ann 2019 Apr-Jun;11(2):119-1252019-04-01 00:00:002019-04-01 00:00:00New treatment modalities with vaccine therapy in renal cell carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-04-01 / Anticancer Res 2019 Apr;39(4):2043-2051
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-04-01 / Anticancer Res 2019 Apr;39(4):2043-20512019-04-01 00:00:002021-11-15 20:00:34Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-04-01 / Stem Cells Int 2019;2019:5680327
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-04-01 / Stem Cells Int 2019;2019:56803272019-04-01 00:00:002019-04-01 00:00:00A Potential Antitumor Effect of Dendritic Cells Fused with Cancer Stem Cells in Hepatocellular Carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-04-01 / Melanoma Res. 2019 04;29(2):109-118
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-04-01 / Melanoma Res. 2019 04;29(2):109-1182019-04-01 00:00:002019-07-01 09:14:32Melanoma vaccines: clinical status and immune endpoints
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-03-20 / Rev Mal Respir 2019 Mar;36(3):415-425
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-03-20 / Rev Mal Respir 2019 Mar;36(3):415-4252019-03-20 00:00:002019-03-20 00:00:00[Vaccines for the treatment of non-small cell lung cancer]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-03-05 / Cancers (Basel) 2019 Mar;11(3)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-03-05 / Cancers (Basel) 2019 Mar;11(3)2019-03-05 00:00:002019-03-05 00:00:00Recent Advances in Cancer Stem Cell-Targeted Immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-03-03 / Br. J. Haematol. 2019 May;185(4):679-690
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-03-03 / Br. J. Haematol. 2019 May;185(4):679-6902019-03-03 00:00:002019-07-01 09:16:10Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-03-01 / J Clin Oncol 37, 2019 (suppl 8; abstr TPS10)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-03-01 / J Clin Oncol 37, 2019 (suppl 8; abstr TPS10)2019-03-01 00:00:002020-05-06 15:08:24Randomized phase II trial of patient-specific dendritic cell vaccines loaded with autologous tumor antigens versus autologous monocytes in patients with primary advanced ovarian cancer.
